Patient demographics and baseline characteristics
| Patients who provided data# | Result | |
| Age years | 1009 | 69.6±8.47 |
| Male | 1009 | 807 (80.0) |
| Ethnicity | 758 | |
| White | 753 (99.3) | |
| Other¶ | 5 (0.7) | |
| BMI kg·m−2 | 1006 | 27.8±4.57 |
| Smoking status | 1004 | |
| Current smoker | 25 (2.5) | |
| Ex-smoker | 602 (60.0) | |
| Never-smoker | 377 (37.5) | |
| Patients with IPF | 1009 | 1006 (99.7) |
| Time since IPF diagnosis years | 1006 | 1.7±3.0 |
| Patients with other reason for pirfenidone prescription+ | 1009 | 3 (0.3) |
| Supplementary oxygen use | 1006 | 277 (27.5) |
| FVC L | 970 | |
| Mean±sd | 2.6±0.78 | |
| Median (range) | 2.5 (0.7–5.0) | |
| FVC % pred | 968 | |
| Mean±sd | 66.0±16.1 | |
| Median (range) | 64.8 (21–121) | |
| FVC% pred <50% | 968 | 144 (14.9) |
| FEV1 L | 975 | |
| Mean±sd | 2.1±0.6 | |
| Median (range) | 2.1 (0.0–4.3) | |
| Liver function test | ||
| ALT | 961 | |
| <1.5×ULN | 947 (98.5) | |
| 1.5– <3.0×ULN | 14 (1.5) | |
| ≥3.0×ULN | 0 (0.0) | |
| AST | 745 | |
| <1.5×ULN | 736 (98.8) | |
| 1.5– <3.0×ULN | 9 (1.2) | |
| ≥3.0×ULN | 0 (0.0) | |
| Total bilirubin | 847 | |
| <1.5×ULN | 842 (99.4) | |
| 1.5– <3.0×ULN | 5 (0.6) | |
| ≥3.0×ULN | 0 (0.0) | |
| One or more ongoing medical conditions§ other than IPFƒ | 1009 | 921 (91.3) |
| Hypertension | 423 (41.9) | |
| Gastro-oesophageal reflux disease | 166 (16.5) | |
| Hypercholesterolaemia | 121 (12.0) | |
| Coronary artery disease | 106 (10.5) | |
| Diabetes mellitus | 97 (9.6) | |
| Type 2 diabetes mellitus | 87 (8.6) | |
| Sleep apnoea syndrome | 81 (8.0) | |
| Osteoarthritis | 63 (6.2) | |
| Cough | 56 (5.6) | |
| Benign prostatic hyperplasia | 55 (5.5) | |
| Hypothyroidism | 55 (5.5) | |
| Atrial fibrillation | 53 (5.3) | |
| Hyperlipidaemia | 52 (5.2) | |
| Obesity | 52 (5.2) | |
| Depression | 50 (5.0) | |
| Pre-baseline exposure to pirfenidone | ||
| Patients | 319 (31.6) | |
| Days | 15.0±9.3 |
Data are presented as n, mean±sd or n (%), unless otherwise stated. BMI: body mass index; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; ALT: alanine aminotransferase; ULN: upper limit of normal; AST: aspartate aminotransferase. #: number of patients who had values for select parameters; ¶: includes Asian, Black or African-American, or any other ethnicities reported; +: includes two patients with extrinsic allergic alveolitis and one patient with nonspecific interstitial pneumonia; §: each medical condition was recorded by investigators using the Medical Dictionary for Regulatory Activities version 19.0 (www.meddra.org) system organ class and preferred term; ƒ: occurring in ≥5% of patients in PASSPORT.